The Abdel-Mohsen lab findings shed light on how sugar molecules in the blood of people living with HIV may accelerate biological aging PHILADELPHIA, PA, April 10, 2024 (Korea Bizwire) – The Wistar Institute’s associate professor Mohamed Abdel-Mohsen, Ph.D., along with his team and collaborators, has identified sugar abnormalities in the blood that may promote biological aging and [...]
BOSTON, Dec. 28 (Korea Bizwire) – Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, today released the latest 2023 global clinical trial landscape report on HIV, a condition now affecting more than 39 million people. The Novotech research analyst team provides these expert reports on a monthly basis, completely free of charge. These [...]
SEOUL, July 27 (Korea Bizwire) — There has been an increasing number of human immunodeficiency virus (HIV) infections in South Korea due to same-sex contact in the last few years, data showed Wednesday. According to the Korea Disease Control and Prevention Agency, there were 19,001 cases of HIV infection between 1985 and 2022, excluding foreigners. [...]
PHILADELPHIA, PA, Jan. 19 (Korea Bizwire) — amfAR, The Foundation for AIDS Research, has awarded Luis J. Montaner, D.V.M., D.Phil., in collaboration with Mohamed Abdel-Mohsen, Ph.D., a Target Grant for $397,663 over two years. Montaner, who leads The Wistar Institute’s HIV Research Program, is studying the ability of a type of immune cell known as natural killer (NK) cells [...]
SEOUL, Aug. 22 (Korea Bizwire) — The number of people living in South Korea that have tested positive for human immunodeficiency virus (HIV) have drastically fallen since the coronavirus outbreak, primarily due to the suspension of HIV-exclusive testing programs and anonymous examinations at most public health clinics, a report said Sunday. The Korea Disease Control [...]
DURHAM, N.C., July 28 (Korea Bizwire) — Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084 long-acting cabotegravir (CAB) for pre-exposure prophylaxis (PrEP) study at the AIDS 2022 conference in Montreal. New findings show reductions in HIV incidence were sustained in the 12 months following trial unblinding (November 5, 2020, through [...]
DURHAM, N.C., Dec. 21 (Korea Bizwire) — Data from the HIV Prevention Trials Network (HPTN) studies HPTN 083 and HPTN 084 helped provide important information for yesterday’s decision by the U.S. Food and Drug Administration (FDA) to approve ViiV Healthcare’s long-acting cabotegravir (CAB-LA) injections for the prevention of HIV. Sponsored and co-funded by the National [...]
SEOUL, Dec. 4 (Korea Bizwire) — The Korea Disease Control and Prevention Agency announced Thursday that new guidelines on treating human immunodeficiency virus (HIV) patients have been published. The guide includes eight recommendations for the healthcare workers, caretakers, and other related personnel. On the patient’s right to health, the guide proclaims that all patients have [...]
DURHAM, N.C., Nov. 30 (Korea Bizwire) — Drs. Myron S. Cohen and Wafaa M. El-Sadr, principal investigators of the HIV Prevention Trials Network (HPTN), in collaboration with FHI 360, have received a seven-year award from the U.S. National Institutes of Health as part of the next funding cycle (2020-2027) for the Network. The core and [...]
Durham, N.C., Nov. 9 (Korea Bizwire) — Researchers from the HIV Prevention Trials Network (HPTN) announced today data from the HPTN 084 clinical trial indicate that a pre-exposure prophylaxis (PrEP) regimen of long-acting cabotegravir (CAB LA) injections once every eight weeks was safe and superior to daily oral tenofovir/emtricitabine (FTC/TDF) for HIV prevention among cisgender women in sub-Saharan Africa. During a planned review of study data, an independent Data and Safety Monitoring Board (DSMB) recommended the study sponsor―the National Institute of Allergy and Infectious Diseases [...]